1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Bausch Health Companies Inc.

Bausch Health Companies Inc.

BHC
Bausch Health Companies Inc.US flagNew York Stock Exchange
6.89
USD
-0.04
- -
2.58BMarket Cap
Bausch Health Companies Inc.
BHC
(New York Stock Exchange)

Recent

price

6.89

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6.03
7.97
11.39
17.97
24.47
- -
27.85
24.91
23.95
24.43
22.61
23.47
22.39
23.96
27.2
27.46
29.06
Revenue per Share
-1.06
0.52
-0.38
-2.7
2.63
- -
-6.94
6.86
-11.86
-5.08
-1.58
-2.64
-0.62
-1.62
-0.13
0.42
-2.94
Basic EPS, GAAP
0.83
0.84
1.56
2.67
5.49
- -
5.17
5.58
3.62
3.47
2.26
3.18
-2.74
2.08
3.55
2.66
3.73
Free Cash Flow per Basic Share
1.82
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
16.24
12.83
12.23
15.37
15.79
17.23
9.06
16.77
7.81
3.02
1.51
-0.29
-1.91
-2.8
-3.48
-1.5
-4.74
Book Value per Share
-14.76
-23.8
-35.32
-52.49
-45.93
-104.18
-90.64
-71.56
-64.05
-63.15
-58.96
-54.29
-49.85
-51.09
-48.71
-44.44
-42.1
Tangible Book Value per Share
196
305
305
321
335
- -
347
350
350
352
355
359
363
365
354
374
374
Basic Weighted Avg Shares
1,181
2,427
3,480
5,770
8,206
10,447
9,674
8,724
8,380
8,601
8,027
8,434
8,124
8,757
9,625
10,266
10,853
Sales/Revenue/Turnover
13.4
22.06
21.45
8.67
27.43
23.6
11.63
6.22
5.95
14.98
15.97
18.59
17.12
18.27
19.26
21.28
25.44
Operating Margin (%)
255
613
986
2,016
1,614
2,467
2,866
2,858
2,819
2,075
1,825
1,552
1,394
1,264
1,267
1,208
1,172
Depreciation Expense
-208
160
-116
-866
881
-292
-2,409
2,404
-4,148
-1,788
-560
-948
-225
-592
-46
157
-1,098
Net Income, GAAP
- -
- -
- -
- -
16.51
- -
- -
- -
- -
- -
- -
- -
- -
- -
143.11
67.3
326.19
Effective Tax Rate (%)
-17.62
6.57
-3.33
-15.01
10.74
-2.8
-24.9
27.56
-49.5
-20.79
-6.98
-11.24
-2.77
-6.76
-0.48
1.53
-10.12
Profit Margin (%)
328
433
955
1,373
1,423
194
1,468
478
375
721
429
409
306
1,294
-978
1,977
1,978
Working Capital
3,574
6,540
10,535
17,163
15,228
30,265
29,845
25,235
24,077
24,661
23,925
22,654
20,334
21,938
18,942
20,615
19,898
LT Debt
4,911
3,930
3,717
5,233
5,402
6,029
3,258
5,944
2,815
1,136
605
-34
260
-82
-322
377
-802
Total Equity
- -
- -
- -
- -
8.65
- -
- -
- -
- -
- -
- -
- -
- -
- -
-3.66
3.36
- -
Return on Invested Capital (%)
- -
- -
- -
- -
7.83
- -
- -
- -
- -
- -
- -
- -
- -
- -
-2.84
3.38
6.82
Return on Capital (%)
-6.65
3.61
-3.03
-19.6
16.95
-5.22
-53.17
53.42
-96.67
-94.2
-70.09
-53.11
-17.57
-64
-7.02
20.73
67.98
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
236
900
881
LT Borrowings
20,592
19,875
19,875
LT Finance Leases
23
20
23
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
371
373
374
Market Capitalization
2,575
2,017
1,843

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,157
5,978
6,522
Cash, Cash Equivalents & STI
1,309
1,299
1,825
Accounts Receivable, Net
2,351
2,191
2,263
Inventories
1,629
1,601
1,602
Total Current Liabilities
4,180
4,530
4,544
Payables & Accruals
2,560
2,478
2,468
ST Debt
236
900
881
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-114.88%
-205.25%
-217.08%
Free Cash Flow
-34.89%
-55.31%
-21%
Net Income, GAAP
-25.03%
-75.48%
-441.3%
Sales/Revenue/Turnover
0.06%
5.15%
6.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,153
2,403
2,510
2,559
9,625
2025
2,259
2,530
2,681
2,796
10,266
2026
2,524
2,852
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.17
0.03
-0.23
0.25
-0.13
2025
-0.16
0.4
0.48
-0.3
0.42
2026
-3.82
0.69
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Avivagen Inc. (VIVXF)
Argent BioPharma Limited (RGT.L)
Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
OWC Pharmaceutical Research Corp. (OWCP)
Rua Bioscience Limited (RUA.NZ)
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (603707.SS)
Business
Bausch Health Companies Inc. develops, manufactures and markets a diversified portfolio of branded pharmaceuticals, generic pharmaceuticals, over-the-counter products and medical devices focused on gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics and ophthalmology; core offerings span Bausch + Lomb vision care products including contact lenses, intraocular lenses and ophthalmic surgical equipment, Salix gastrointestinal therapies such as Xifaxan, Ortho Dermatologics treatments like Retin-A Micro and Arazlo, Diversified neurology and pain medications including Wellbutrin and Relistor, Solta Medical aesthetic devices such as Thermage and Clear + Brilliant, and international branded generics and OTC products. Founded in 1959 and headquartered in Laval, Quebec, Canada, with U.S. operations in Bridgewater, New Jersey, the company conducts business directly or indirectly in over 90 countries across North America, Europe, the Middle East, Africa, Asia Pacific and Latin America through segments including Bausch + Lomb, Salix, International Rx, Ortho Dermatologics and Diversified Products. Recent developments include the completion of the DURECT Corporation acquisition in September 2025 adding larsucosterol, an FDA Breakthrough Therapy candidate for alcohol-associated hepatitis, to its hepatology pipeline; commercial expansion of the OraPharma division into Canada and Puerto Rico in November 2025 to enhance access to periodontal treatments like Arestin; acquisition of Chinese aesthetics distributor Wuhan Shibo Zhenmei Technology Co., Ltd. in December 2025; Canadian approvals and launches of CABTREO acne therapy in October 2024 and Thermage FLX in April 2025; and international regulatory nods for Clear + Brilliant Touch in multiple Asia Pacific markets in 2024-2025.

Company News

APIChatGPT

  • prnewswire.com

    Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners

  • seekingalpha.com

    Bausch Health: Q2 Beat And Cheap, But Debt Overhang Remains Substantial

  • zacks.com

    Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term

  • fool.com

    Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month

  • prnewswire.com

    Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board

  • businesswire.com

    Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

  • zacks.com

    BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised

  • seekingalpha.com

    Bausch Health Companies Inc. (BHC) Q2 2026 Earnings Call Transcript

  • zacks.com

    Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates

  • marketbeat.com

    Bausch Health Cos Q2 Earnings Call Highlights

  • zacks.com

    Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say

  • prnewswire.com

    BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE

  • reuters.com

    Bausch to stop glaucoma eye drop development after trial miss

  • prnewswire.com

    Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026

  • prnewswire.com

    Michael Goettler Resigns from Bausch Health's Board of Directors

  • zacks.com

    Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound?

  • prnewswire.com

    Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China

  • seekingalpha.com

    Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

  • prnewswire.com

    Bausch Health Announces 2026 Annual Meeting of Shareholder Results

  • seekingalpha.com

    Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript